We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The deal will give Arcturus a route to public investors at a time when interest in RNA therapies is flying high on the back of Alnylam’s phase 3 success.